[Anti-vascular endothelian growth factor therapy in the field of oncology].

Through many years the ability to suppress angiogenesis has been exploited in the field of oncology. The efficiency is well-documented and the indications are constantly growing, although the impact often is rather limited, as we argue in this review. Recent evidence suggests that inhibition of angiogenesis may be clinically meaningful through several lines of treatment but lack of biomarkers limits an individualised approach. The tumour microenvironment is anti-immune and a combination of anti-angiogenic drugs and immunotherapy has demonstrated impressive results and may alter the therapy in the years to come.